Predictive Biomarkers Market Analysis

  • Report ID: 3175
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Predictive Biomarkers Market Analysis

Application (Screening, Analysis, Diagnosis, Prediction, Monitoring)

The prediction segment in the predictive biomarkers market is estimated to gain a robust revenue share in the coming years owing to rising demand for measuring the likelihood of results of any treatment procedure. Predictive biomarkers are frequently employed at all stages of the drug discovery and development process to show the connection between the biomarker and treatment outcome and determine whether a disease or condition is present. Owing to their ability to predict whether a patient will respond to a specific chemotherapy, predictive biomarkers aid in the optimization of treatment choices, and are highly used to forecast the effects of treatment on patients, which helps medical professionals to provide specific medications.

End-Use (Hospitals, Specialty Clinics, Research Institutes)

The research institutes segment in the predictive biomarkers market is set to garner a notable share shortly driven by the investment made by various key market players for the creation of novel biomarkers for diagnostic and therapeutic purposes, along with large-scale funds from the government and private organizations which have been given to groups working on the development of new drugs. Research centers contribute to advancements in technology that facilitate biomarker identification associated with specific diseases. Besides this, they conduct clinical trials to assess the utility of predictive biomarkers and promote awareness regarding the benefits of these biomarkers.

Our in-depth analysis of the global market includes the following segments:

          Indication

  • Cancer
  • Metabolic Disease
  • Neurological Disease

           Application

  • Screening
  • Analysis
  • Diagnosis
  • Prediction
  • Monitoring

          End-Use

  • Hospitals
  • Specialty Clinics
  • Research Institutes
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3175
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of predictive biomarkers is evaluated at USD 21 Billion.

The predictive biomarkers market size was over USD 20.3 Billion in 2023 and is likely to exceed USD 29.5 Billion by the end of 2036, growing at over 18.9% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of chronic diseases, such as cancer, and diabetes across the globe and the growing geriatric population are the major factors driving the growth of the market.

North America is predicted to account for the largest share of 35% by 2036, backed by the advanced research and development activities in the healthcare sector.

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH, Danaher Corporation, Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., Meso Scale Diagnostics, LLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample